Eli Lilly & Co. vs Insulet Corporation
LLY vs PODD — side-by-side comparison from reported financials. LLY leads 8, PODD leads 3 of 11 comparable metrics.
Eli Lilly & Co.
LLY · Healthcare
$1 177.20+0.65%Solid
Insulet Corporation
PODD · Healthcare
$135.28+0.60%Strong
| Metric | LLY | PODD |
|---|---|---|
| Price | $1 177.20 | $135.28 |
| Market cap | $1.05T | $9.38B |
| Revenue (TTM) | $79.7B | $3.05B |
| Revenue growth | +31.7% | +27.5% |
| Net margin | 33.5% | 12.3% |
| Free cash flow | $18.2B | $294M |
| Net cash (debt) | ($35.2B) | ($215M) |
| 1-year price return | +37.6% | -57.8% |
| P/E | 41.6 | 25.0 |
| P/E vs own history (cheap-side %) | 88% | 99% |
| Dividend yield | 0.52% | — |
| Return on equity | 93% | 17% |
| Altman Z-score | 7.10 | 4.61 |
| CV checks passed | 11 of 11 | 10 of 11 |
| Employees | 50,000 | 5,400 |
Full résumé-style profiles: LLY CV · PODD CV
Green marks the stronger side on comparable metrics. Figures are derived from company filings and may be delayed, restated or incomplete — information, not investment advice.